{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T14:44:07Z","timestamp":1750949047560},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00115-021-01189-8","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T02:47:13Z","timestamp":1632451633000},"page":"612-617","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sumatriptan 3\u202fmg subkutan"],"prefix":"10.1007","volume":"93","author":[{"given":"Charly","family":"Gaul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"F\u00f6rderreuther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"issue":"1","key":"1189_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.13301","volume":"58","author":"R Agosti","year":"2018","unstructured":"Agosti\u00a0R (2018) Migraine burden of disease: from the patient\u2019s experience to a\u00a0socio-economic view. Headache 58(1):17\u201332","journal-title":"Headache"},{"key":"1189_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.013","author":"DC Buse","year":"2016","unstructured":"Buse\u00a0DC, Scher\u00a0AI, Dodick\u00a0DW et\u00a0al (2016) Impact of migraine on the family: perspectives of people with migraine and their spouse\/domestic partner in the CaMEO study. Mayo Clin Proc. https:\/\/doi.org\/10.1016\/j.mayocp.2016.02.013","journal-title":"Mayo Clin Proc"},{"key":"1189_CR3","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1185\/030079904X2745","volume":"20","author":"R Cady","year":"2004","unstructured":"Cady\u00a0R, Elkind\u00a0A, Goldstein\u00a0J et al (2004) Randomized, placebo-controlled comparison of early use of frovatriptan in a\u00a0migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin 20:1465\u20131472","journal-title":"Curr Med Res Opin"},{"key":"1189_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10194-016-0717-7","volume":"18","author":"RK Cady","year":"2017","unstructured":"Cady\u00a0RK, Munjal\u00a0S, Cady\u00a0RJ et al (2017) Randomized, double-blind, crossover study comparing DFN-11 injection (3\u202fmg subcutaneous sumatriptan) with 6\u202fmg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. J\u00a0Headache Pain 18:17","journal-title":"J Headache Pain"},{"key":"1189_CR5","first-page":"Cd009665","volume":"2","author":"CJ Derry","year":"2012","unstructured":"Derry\u00a0CJ, Derry\u00a0S, Moore\u00a0RA (2012) Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2:Cd9665","journal-title":"Cochrane Database Syst Rev"},{"key":"1189_CR6","volume-title":"Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne","author":"H-C Diener","year":"2018","unstructured":"Diener\u00a0H\u2011C, Gaul\u00a0C, Kropp\u00a0P et al (2018) Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne (S1-Leitlinie, 2018)"},{"key":"1189_CR7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(88)92122-8","volume":"1","author":"A Doenicke","year":"1988","unstructured":"Doenicke\u00a0A, Brand\u00a0J, Perrin\u00a0VL (1988) Possible benefit of GR43175, a\u00a0novel 5\u2011HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1:1309\u20131311","journal-title":"Lancet"},{"key":"1189_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1526-4610.2004.04074.x","volume":"44","author":"AJ Dowson","year":"2004","unstructured":"Dowson\u00a0AJ, Massiou\u00a0H, Lainez\u00a0JM et\u00a0al (2004) Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 44:318\u2013322","journal-title":"Headache"},{"key":"1189_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1600-0404.1993.tb04189.x","volume":"88","author":"K Ekbom","year":"1993","unstructured":"Ekbom\u00a0K, Monstad\u00a0I, Prusinski\u00a0A et\u00a0al (1993) Subcutaneous sumatriptan in the acute treatment of cluster headache: a\u00a0dose comparison study. The sumatriptan cluster headache study group. Acta Neurol Scand 88:63\u201369","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1189_CR10","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1007\/BF01642910","volume":"238","author":"FB Ensink","year":"1991","unstructured":"Ensink\u00a0FB (1991) Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan international study group. J\u00a0Neurol 238(1):S66\u201369","journal-title":"J Neurol"},{"key":"1189_CR11","volume-title":"MIGRAPEN \u00ae 3\u202fmg\/0,5\u202fml Injektionsl\u00f6sung im Fertigpen","author":"Fachinfo Service","year":"2021","unstructured":"Fachinfo Service (2021) MIGRAPEN \u00ae 3\u202fmg\/0,5\u202fml Injektionsl\u00f6sung im Fertigpen"},{"key":"1189_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1526-4610.2004.04030.x","volume":"44","author":"AW Fox","year":"2004","unstructured":"Fox\u00a0AW (2004) Onset of effect of 5\u2011HT1B\/1D agonists: a\u00a0model with pharmacokinetic validation. Headache 44:142\u2013147","journal-title":"Headache"},{"issue":"2","key":"1189_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000119530","volume":"34","author":"PJ Goadsby","year":"1994","unstructured":"Goadsby\u00a0PJ (1994) The clinical profile of sumatriptan: cluster headache. Eur Neurol 34(2):35\u201339","journal-title":"Eur Neurol"},{"key":"1189_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1468-2982.2008.01546.x","volume":"28","author":"PJ Goadsby","year":"2008","unstructured":"Goadsby\u00a0PJ, Zanchin\u00a0G, Geraud\u00a0G et al (2008) Early vs. non-early intervention in acute migraine-\u2019Act when Mild (AwM)\u2019. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 28:383\u2013391","journal-title":"Cephalalgia"},{"key":"1189_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1526-4610.2005.05189.x","volume":"45","author":"N Gregor","year":"2005","unstructured":"Gregor\u00a0N, Schlesiger\u00a0C, Akova-Ozt\u00fcrk\u00a0E et al (2005) Treatment of cluster headache attacks with less than 6\u202fmg subcutaneous sumatriptan. Headache 45:1069\u20131072","journal-title":"Headache"},{"key":"1189_CR16","volume-title":"Arztreport 2017. Schriftenreihe zur Gesundheitsanalyse","author":"TG Grobe","year":"2017","unstructured":"Grobe\u00a0TG, Steinmann\u00a0S, Szecsenyi\u00a0J (2017) Arztreport 2017. Schriftenreihe zur Gesundheitsanalyse Bd. 1"},{"key":"1189_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-018-0881-z","volume":"19","author":"S Landy","year":"2018","unstructured":"Landy\u00a0S, Munjal\u00a0S, Brand-Schieber\u00a0E et al (2018) Efficacy and safety of DFN-11 (sumatriptan injection, 3\u202fmg) in adults with episodic migraine: a\u00a0multicenter, randomized, double-blind, placebo-controlled study. J\u00a0Headache Pain 19:69","journal-title":"J Headache Pain"},{"key":"1189_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s10194-018-0882-y","volume":"19","author":"S Landy","year":"2018","unstructured":"Landy\u00a0S, Munjal\u00a0S, Brand-Schieber\u00a0E et al (2018) Efficacy and safety of DFN-11 (sumatriptan injection, 3\u202fmg) in adults with episodic migraine: an 8\u2011week open-label extension study. J\u00a0Headache Pain 19:70","journal-title":"J Headache Pain"},{"key":"1189_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1526-4610.2005.05072.x","volume":"45","author":"SH Landy","year":"2005","unstructured":"Landy\u00a0SH, Mcginnis\u00a0JE, Mcdonald\u00a0SA (2005) Pilot study evaluating preference for 3\u2011mg versus 6\u2011mg subcutaneous sumatriptan. Headache 45:346\u2013349","journal-title":"Headache"},{"key":"1189_CR20","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1073\/pnas.0306147101","volume":"101","author":"D Levy","year":"2004","unstructured":"Levy\u00a0D, Jakubowski\u00a0M, Burstein\u00a0R (2004) Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B\/1D receptor agonists. Proc Natl Acad Sci USA 101:4274\u20134279","journal-title":"Proc Natl Acad Sci USA"},{"key":"1189_CR21","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/head.13588","volume":"59","author":"RB Lipton","year":"2019","unstructured":"Lipton\u00a0RB, Munjal\u00a0S, Buse\u00a0DC et\u00a0al (2019) Unmet acute treatment needs from the 2017 migraine in America symptoms and treatment study. Headache 59:1310\u20131323","journal-title":"Headache"},{"key":"1189_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1046\/j.1526-4610.2001.041007646.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton\u00a0RB, Stewart\u00a0WF, Diamond\u00a0S et\u00a0al (2001) Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache 41:646\u2013657","journal-title":"Headache"},{"key":"1189_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1526-4610.2010.01625.x","volume":"50","author":"EA Macgregor","year":"2010","unstructured":"Macgregor\u00a0EA, Victor\u00a0TW, Hu\u00a0X et al (2010) Characteristics of menstrual vs nonmenstrual migraine: a\u00a0post hoc, within-woman analysis of the usual-care phase of a\u00a0nonrandomized menstrual migraine clinical trial. Headache 50:528\u2013538","journal-title":"Headache"},{"key":"1189_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/archneur.1992.00530360073020","volume":"49","author":"NT Mathew","year":"1992","unstructured":"Mathew\u00a0NT, Dexter\u00a0J, Couch\u00a0J et\u00a0al (1992) Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US sumatriptan research group. Arch Neurol 49:1271\u20131276","journal-title":"Arch Neurol"},{"key":"1189_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1055\/s-0037-1616368","volume":"35","author":"A May","year":"2016","unstructured":"May\u00a0A, Evers\u00a0S, Br\u00f6ssner\u00a0G et al (2016) Leitlinie zur Diagnostik, Therapie und Prophylaxe von Cluster-Kopfschmerz, anderen trigeminoautonomen Kopfschmerzen, schlafgebundenem Kopfschmerz und idiopathisch stechenden Kopfschmerzen. Nervenheilkunde 35:137\u2013151","journal-title":"Nervenheilkunde"},{"key":"1189_CR26","unstructured":"Moore A, Mcquay H (2002) Migraine special issue. http:\/\/www.bandolier.org.uk\/Extraforbando\/migspec.pdf. Zugriff: 13.09.2021"},{"key":"1189_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10194-020-01099-1","volume":"21","author":"B M\u00fcller","year":"2020","unstructured":"M\u00fcller\u00a0B, Dresler\u00a0T, Gaul\u00a0C et al (2020) Use of outpatient medical care by headache patients in Germany: a\u00a0population-based cross-sectional study. J\u00a0Headache Pain 21:49","journal-title":"J Headache Pain"},{"key":"1189_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jamaneurol.2017.5144","volume":"75","author":"Y Orlova","year":"2018","unstructured":"Orlova\u00a0Y, Rizzoli\u00a0P, Loder\u00a0E (2018) Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 75:566\u2013572","journal-title":"JAMA Neurol"},{"key":"1189_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1046\/j.1526-4610.1998.3803184.x","volume":"38","author":"V Pfaffenrath","year":"1998","unstructured":"Pfaffenrath\u00a0V, Cunin\u00a0G, Sjonell\u00a0G et\u00a0al (1998) Efficacy and safety of sumatriptan tablets (25\u202fmg, 50\u202fmg, and 100\u202fmg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 38:184\u2013190","journal-title":"Headache"},{"key":"1189_CR30","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/j.1526-4610.2006.00608.x","volume":"46","author":"W Pryse-Phillips","year":"2006","unstructured":"Pryse-Phillips\u00a0W, Aub\u00e9\u00a0M, Bailey\u00a0P et al (2006) A clinical study of migraine evolution. Headache 46:1480\u20131486","journal-title":"Headache"},{"key":"1189_CR31","first-page":"227","volume-title":"The headaches","author":"BK Rasmussen","year":"2000","unstructured":"Rasmussen\u00a0BK, Stewart\u00a0WF (2000) Epidemiology yof migraine. In: Oleson\u00a0J, Tfelt-Hansen\u00a0P, Welch\u00a0KMA (Hrsg) The headaches. Raven Press, New York, S 227\u2013233"},{"issue":"14","key":"1189_CR32","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1177\/0333102420944842","volume":"40","author":"AH Seddik","year":"2020","unstructured":"Seddik\u00a0AH, Branner\u00a0JC, Ostwald\u00a0DA et\u00a0al (2020) The socioeconomic burden of migraine: an evaluation of productivity losses due to migraine headaches based on a population study in Germany. Cephalalgia 40(14):1551\u20131560. https:\/\/doi.org\/10.1177\/0333102420944842","journal-title":"Cephalalgia"},{"key":"1189_CR33","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1212\/WNL.44.12_Suppl_10.S24","volume":"44","author":"WF Stewart","year":"1994","unstructured":"Stewart\u00a0WF, Shechter\u00a0A, Lipton\u00a0RB (1994) Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 44:S24\u201339","journal-title":"Neurology"},{"key":"1189_CR34","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner\u00a0LJ, Nichols\u00a0E, Steiner\u00a0TJ et al (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a\u00a0systematic analysis for the global burden of disease study 2016. Lancet Neurol 17:954\u2013976","journal-title":"Lancet Neurol"},{"key":"1189_CR35","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","volume":"59","author":"SJ Tepper","year":"2002","unstructured":"Tepper\u00a0SJ, Rapoport\u00a0AM, Sheftell\u00a0FD (2002) Mechanisms of action of the 5\u2011HT1B\/1D receptor agonists. Arch Neurol 59:1084\u20131088","journal-title":"Arch Neurol"},{"key":"1189_CR36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1046\/j.1468-2982.1993.1304238.x","volume":"13","author":"P Tfelt-Hansen","year":"1993","unstructured":"Tfelt-Hansen\u00a0P (1993) Sumatriptan for the treatment of migraine attacks\u2014a review of controlled clinical trials. Cephalalgia 13:238\u2013244","journal-title":"Cephalalgia"},{"key":"1189_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0333102416644745","volume":"37","author":"PC Tfelt-Hansen","year":"2017","unstructured":"Tfelt-Hansen\u00a0PC (2017) Delayed absorption of many (paracetamol, aspirin, other NSAIDs and zolmitriptan) but not all (sumatriptan, rizatriptan) drugs during migraine attacks and most likely normal gastric emptying outside attacks. A review. Cephalalgia 37:892\u2013901","journal-title":"Cephalalgia"},{"key":"1189_CR38","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJM199108013250505","volume":"325","author":"The Sumatriptan Cluster Headache Study Group","year":"1991","unstructured":"The Sumatriptan Cluster Headache Study Group (1991) Treatment of acute cluster headache with sumatriptan. The sumatriptan cluster headache study group. N\u00a0Engl J Med 325:322\u2013326","journal-title":"N Engl J Med"},{"key":"1189_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1177\/0333102417698953","volume":"38","author":"W van Oosterhout","year":"2018","unstructured":"van Oosterhout\u00a0W, van Someren\u00a0E, Schoonman\u00a0GG et\u00a0al (2018) Chronotypes and circadian timing in migraine. Cephalalgia 38:617\u2013625","journal-title":"Cephalalgia"},{"key":"1189_CR40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1526-4610.2010.01778.x","volume":"51","author":"G Viticchi","year":"2011","unstructured":"Viticchi\u00a0G, Silvestrini\u00a0M, Falsetti\u00a0L et\u00a0al (2011) Time delay from onset to diagnosis of migraine. Headache 51:232\u2013236","journal-title":"Headache"},{"key":"1189_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s10194-019-1034-8","volume":"20","author":"C Ziegeler","year":"2019","unstructured":"Ziegeler\u00a0C, Brauns\u00a0G, J\u00fcrgens\u00a0TP et\u00a0al (2019) Shortcomings and missed potentials in the management of migraine patients\u2014experiences from a\u00a0specialized tertiary care center. J\u00a0Headache Pain 20:86","journal-title":"J Headache Pain"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01189-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-021-01189-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01189-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T14:03:10Z","timestamp":1655301790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-021-01189-8"}},"subtitle":["Klinische Relevanz in der Akuttherapie der Migr\u00e4ne trotz Dosisreduktion"],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1007\/s00115-021-01189-8","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"23 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Gaul erhielt in den letzten 3\u00a0Jahren Honorare und Reisekostenerstattung f\u00fcr Beratert\u00e4tigkeit und Referentent\u00e4tigkeiten von Lilly, Sanofi, Novartis Pharma, TEVA-Ratiopharm, Allergan Pharma, Hormosan Perfood und Gruenthal. Er besitzt keine Aktien oder Firmenanteile von pharmazeutischen Unternehmen. S.\u00a0F\u00f6rderreuther erhielt in den letzten 5\u00a0Jahren Honorare und Reisekostenerstattung f\u00fcr Beratert\u00e4tigkeit und Referentent\u00e4tigkeiten von Eli Lilly, Sanofi, Novartis, TEVA, Allergan, AstraZeneca, Hormosan und recordati Pharma. Sie besitzt keine Aktien oder Firmenanteile von pharmazeutischen Unternehmen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}